期刊文献+

来氟米特联合甲氨蝶呤治疗类风湿关节炎的临床疗效 被引量:13

下载PDF
导出
摘要 目的:比较来氟米特(LEF)联合甲氨蝶呤(MTX)与柳氮磺氨嘧啶(SSZ)联合甲氨蝶呤治疗类风湿关节炎的临床疗效、不良反应及实验室指标的变化。方法:将81例类风湿关节炎患者分为两组,LEF+MTX组42例,SSZ+MTX组39例,LEF20mg/d口服,MTX每周7.5mg口服,SSZ1.0g,2次/d口服。观察握力、晨僵、关节肿胀数、病人评价、医生评价、血沉、C反蛋白、类风湿因子滴度等指标。结果:从临床症状、体征、关节功能改善方面,MTX+LEF联合治疗组优于MTX+SSZ联合治疗组。观察时间有待进一步延长,追踪随访。结论:两组治疗方案疗效均较满意,大多数患者耐受性好,不良反应轻。
作者 祁艳萍 赵伟
出处 《中国医药导报》 CAS 2007年第06Z期51-52,共2页 China Medical Herald
  • 相关文献

参考文献3

二级参考文献30

  • 1[1]Smolen JS,Kalden JR,Scott DI,et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised,multicentre trial[J]. Lancet, 1999, 353(9149): 259.
  • 2[2]Cherwinski HM, Byars N, Ballaron SJ, et al. Leflunomide interferes with pyramidine nucleotide biosynthesis [J].Inflamm Res, 1995, 44(8): 317.
  • 3[3]Herrmann M, Frangou CG, Kirschbaum B. Cell cycle control of the de novo pyrimidine synthesis inhibitor leflunomide through the p53 and p21WAF-1 pathways[J].ACR Poster Session,2000, Abstract: 875.
  • 4[4]Xu X, Williams JW, Gong H, et al. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726.Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation[J]. Biochem Pharmacol, 1996, 52(4): 527.
  • 5[5]Klausner RD, Samelson LE. T cell antigen receptor activation pathway: the tyrosine kinase connection[J]. Cell,1991, 64(5): 875.
  • 6[6]Mattar T, Kochhar K, Bartlett R, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide[J]. FEBS Lett, 1993, 334(2): 161.
  • 7[7]Shawver LK, Schwartz DP, Mann E, et al. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N- [4- (trifluoromethyl) -phenyl] 5-methylisoxazole -4- carboxamide[J]. Clin Cancer Res, 1997,3(7): 1167.
  • 8[8]Xu X, Shen J, Mall JW , et al. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide:mechanisms of action[J]. Biochem Phamacol, 1999, 58(9):1405.
  • 9[9]Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726 ) blocks TNF-dependent nuclear factor-κB activation and gene expression [J]. J Immunol, 1999, 162(4): 2095.
  • 10[10]Tomita N, Morishita R, Lan HY, et al. In vivo administration of a nuclear transcription factor-kappaB decoy suppresses experimental crescentic glomerulonephritis[J]. J Am Soc Nephrol, 2000, 11(7): 1244.

共引文献105

同被引文献78

引证文献13

二级引证文献89

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部